.jpg)
.png)
The main goal of lipid testing is accurate identification of persons at high risk for ASCVD and the relevant science continues to evolve. Methods used to measure or calculate LDL-C from conventional lipid measurements are likely to be refined. Specialized evaluations of atherogenic lipid levels are generally not needed to assess patients prior to the initiation of aggressive lipid altering therapy.
all
The U.S. Food and Drug Administration released a Drug Safety Communication on July 20, 2021, concerning the removal of the strongest warning against using statins during pregnancy. The warning states that statins should never be used in any patients during pregnancy.
The NLA has released a Clinical Perspective to provide strategies for early screening and education of the community and their healthcare providers, and offer practical prevention strategies and culturally-tailored dietary advice to lower the rates of ASCVD in this cohort.